Published in Int J Cancer on July 15, 2010
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer (2011) 2.24
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem (2012) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer (2012) 1.23
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer (2011) 1.20
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 1.16
Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer (2016) 1.08
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol (2011) 1.00
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology (2013) 0.98
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer (2013) 0.98
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol (2014) 0.97
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One (2014) 0.97
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis (2011) 0.97
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer (2015) 0.94
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Front Oncol (2013) 0.84
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer (2014) 0.82
The BRAF mutation is associated with the prognosis in colorectal cancer. J Cancer Res Clin Oncol (2014) 0.82
RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol (2016) 0.81
KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol (2015) 0.81
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer (2014) 0.81
Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther (2014) 0.81
The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. PLoS One (2013) 0.81
BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. PLoS Curr (2010) 0.79
Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch (2014) 0.78
BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? Mol Cell Oncol (2015) 0.78
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget (2016) 0.77
A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes. Biomark Res (2015) 0.77
Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases. World J Surg Oncol (2015) 0.77
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol (2016) 0.77
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncol Lett (2015) 0.77
Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. Sensors (Basel) (2015) 0.76
The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res (2014) 0.76
Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PLoS One (2013) 0.76
Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer? Cancer Res Treat (2015) 0.76
Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer (2014) 0.76
DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. Cancer Med (2017) 0.75
Lack of BRAFV600E mutation in stage I and II of colorectal cancer. Gastroenterol Hepatol Bed Bench (2016) 0.75
Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. Oncol Lett (2016) 0.75
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. J Korean Med Sci (2017) 0.75
Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev (2016) 0.75
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. Cancer Biol Ther (2016) 0.75
ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. Oncotarget (2016) 0.75
K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. Int J Biol Markers (2013) 0.75
BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer. Gastroenterol Rep (Oxf) (2013) 0.75
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med (2004) 3.13
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology (2003) 2.27
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab (2012) 2.03
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. World Allergy Organ J (2010) 2.01
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology (2007) 1.81
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology (2005) 1.73
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer (2003) 1.67
Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology (2003) 1.66
Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology (2013) 1.65
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol (2010) 1.58
Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest (2014) 1.54
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol (2003) 1.49
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion (2008) 1.43
Calcifying fibrous tumor of the stomach: clinicopathologic and molecular study of seven cases with literature review and reappraisal of histogenesis. Am J Surg Pathol (2010) 1.43
New GATA1 mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder. Blood (2009) 1.42
Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer (2010) 1.41
Differential diagnosis of IgE-mediated allergy in young children with wheezing or eczema symptoms using a single blood test. Ann Allergy Asthma Immunol (2004) 1.39
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2012) 1.38
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology (2011) 1.26
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol (2010) 1.24
Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res (2008) 1.23
Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol (2007) 1.22
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (2010) 1.21
EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res (2005) 1.21
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res (2002) 1.21
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 1.18
SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer (2003) 1.18
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer (2010) 1.16
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res (2007) 1.15
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (2010) 1.15
Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology (2010) 1.15
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol (2010) 1.14
Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect. Am J Surg Pathol (2008) 1.13
NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer (2005) 1.13
Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol (2008) 1.13
Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol (2007) 1.13
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology (2012) 1.12
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology (2012) 1.11
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer (2012) 1.10
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol (2012) 1.10
Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology (2012) 1.09
The HOX gene network in hepatocellular carcinoma. Int J Cancer (2011) 1.07
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (2011) 1.07
Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol (2009) 1.07
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011) 1.06
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol (2008) 1.06
Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology (2012) 1.05
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol (2012) 1.05
Growth of infants with IgE-mediated cow's milk allergy fed different formulas in the complementary feeding period. Pediatr Allergy Immunol (2007) 1.04
Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J Transl Med (2013) 1.04
Melanoma cells inhibit NK cell functions. Cancer Res (2012) 1.04
Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol (2007) 1.04
RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res (2008) 1.04
Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size. World J Surg (2003) 1.04
Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol (2003) 1.03
Interaction of C/EBPalpha and the glucocorticoid receptor in vivo and in nontransformed human cells. FASEB J (2002) 1.03